Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Endosc. Aug 16, 2019; 11(8): 443-453
Published online Aug 16, 2019. doi: 10.4253/wjge.v11.i8.443
Published online Aug 16, 2019. doi: 10.4253/wjge.v11.i8.443
Potential role of new technological innovations in nonvariceal hemorrhage
David Friedel, Department of Gastroenterology, New York University Winthrop Hospital, Mineola, NY 11501, United States
Author contributions: Friedel D contributed to the manuscript.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: David Friedel, AGAF, MD, Associate Professor, Department of Gastroenterology, New York University Winthrop Hospital, 222 Station Plaza North, Suite 428, Mineola, NY 11501, United States. dfriedel@winthrop.org
Telephone: +1-516-6634623
Received: May 12, 2019
Peer-review started: May 14, 2019
First decision: June 3, 2019
Revised: June 16, 2019
Accepted: July 20, 2019
Article in press: July 3, 2019
Published online: August 16, 2019
Processing time: 96 Days and 8.6 Hours
Peer-review started: May 14, 2019
First decision: June 3, 2019
Revised: June 16, 2019
Accepted: July 20, 2019
Article in press: July 3, 2019
Published online: August 16, 2019
Processing time: 96 Days and 8.6 Hours
Core Tip
Core tip: New devices are available for hemostasis of non-variceal upper gastrointestinal hemorrhage that may supplement or supplant traditional modalities. These devices however have a varying track record in hemostasis with different learning curves, costs and detriments.